- Home
- RFM vs RPTX Comparison
RFM vs RPTX Comparison
Compare RFM & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.63
Company Overview
Basic Information| Metric | RFM | RPTX |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.9M | 92.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RFM | RPTX |
|---|---|---|
| Price | $14.21 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 20.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 9.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,122.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.89 | $0.89 |
| 52 Week High | $16.41 | $2.66 |
Technical Indicators
Market Signals| Indicator | RFM | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 69.79 |
| Support Level | $14.08 | $2.50 |
| Resistance Level | $14.23 | $2.61 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 74.83 | 95.83 |
Price Performance
Historical Comparison RFM
RPTX
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.